Allogene Therapeutics, Inc.

Public Equity (NASDAQ)BiotechnologyCell TherapyAlloCAR T

📍 South San Francisco, CA, USA• Founded 2018

StreetZero Signal 54

Be the first to signal interest

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. It is pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. The company aims to deliver off-the-shelf CAR T cell therapies on-demand, more reliably, and at greater scale.

LATEST FUNDINGRule 144

$49K

Announced 2026-10-21

TOTAL RAISED$532M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Allogene Therapeutics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2018

HQSouth San Francisco, CA, USA

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Total funding reached $532M across 5 rounds since 2016.
Completed $175M public offering of common stock priced at $2.00 per share in April 2026, closing at $200.4M.
Focuses on off-the-shelf allogeneic CAR T therapies for cancer and autoimmune disease.
Headquartered in South San Francisco with 17 institutional investors.
Public company on NASDAQ: ALLO with 56% institutional ownership.

Ask StreetZero about Allogene Therapeutics, Inc.

Put our AI to work on this deal.

What is Allogene Therapeutics, Inc.'s value proposition?Who are Allogene Therapeutics, Inc.'s competitors?Why does this raise matter?Summarize Allogene Therapeutics, Inc. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Crowdstrike Holdings, Inc.

$141.0M

Palo Alto Networks Inc

$201.4M

STOKE THERAPEUTICS, INC.

$38.4M

Lindblad Expeditions Holdings, Inc.

$53.2M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.